Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.
about
Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.Selenium enrichment of broccoli sprout extract increases chemosensitivity and apoptosis of LNCaP prostate cancer cellsAICAR inhibits proliferation and induced S-phase arrest, and promotes apoptosis in CaSki cells.Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.Contextualization of drug-mediator relations using evidence networks.Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cellsMetformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathwayVascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancerPotential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review.Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG.Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma.Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel.Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analoguesRole of activating transcription factor 3 on TAp73 stability and apoptosis in paclitaxel-treated cervical cancer cells.A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.Combined treatment strategies for microtubule stabilizing agent-resistant tumors.Potential biomarkers for paclitaxel sensitivity in hypopharynx cancer cellProteomic analysis reveals tanshinone IIA enhances apoptosis of advanced cervix carcinoma CaSki cells through mitochondria intrinsic and endoplasmic reticulum stress pathways.Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells.Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors.Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2)
P2860
Q30583249-0C4F1C43-D6FA-45E0-A60B-C6BC4B5E6011Q30924425-003FB6C4-7F72-48A4-B823-144BC2FC78DBQ33306763-6B4CD7B0-7898-42A1-AAEE-242AD215BE30Q33382682-00C6F313-0B9F-4DE7-B70F-279998353914Q33401499-48E63FDF-9462-4074-8384-FD5D8D513D9AQ33409908-BC4C7E72-AF5D-4C54-ADC2-C8095B87CE5BQ33638550-85543C46-1241-4680-A8A1-5EC37AA762A1Q33720115-9F662699-8D16-45A5-8EF8-C05A23328658Q33802232-9255FC97-1ACD-4E4D-BC7A-4060F389E138Q34130665-15EB1BF1-96C0-459C-8D42-9B6634AF61A9Q34632966-35402C0D-015D-4A34-AF93-F665D96D7CF4Q35157985-2C3E010F-826E-4BE7-99C7-DF650914AE1FQ35723911-2EC55AA3-378A-46AC-95D1-6F264090CF32Q35877999-0DDDDF5E-C1A0-47E1-953B-5AED048786B0Q35992948-4CE247D7-5BA0-46D7-A267-01FB5F461891Q36206239-B69BB877-756B-4E74-8927-A9E8F6273A03Q36312850-707576CC-2420-451C-9E6F-CC4AF6236B6DQ36663932-C568F711-1B1D-494E-BD19-E7F744DEE066Q36792877-811A1D8D-AFDF-4E29-B681-9AF8628344FFQ36979015-E18D3728-95C5-4BA7-9D6C-15C230F87BD3Q37198034-EE9B77C5-1760-4866-963D-FE12B518D6A0Q37483253-8AE812DF-C8A7-465C-8C49-25F585965ED7Q38739235-63824A56-4D6B-46EE-992F-D8700DB71263Q38908225-876F3961-C018-4034-8951-63FF43274B97Q39051376-B3F44F8F-A58E-447A-A19A-E4A59C8963AEQ39069268-7E72ECD7-75B1-41EA-BABA-FB03AE753ECEQ44638649-8DCE6693-E092-44A5-B56E-3973B922F114Q46342083-7BA4F96D-A749-4C74-A2A7-5DAA6482498AQ54292748-50A92108-DA10-4D83-BF7D-50AFBAB06DBDQ58700608-6F042BB3-D390-436A-A3B5-E03484A00DA8
P2860
Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Inhibition of the mammalian ta ...... of CaSki cells to paclitaxel.
@ast
Inhibition of the mammalian ta ...... of CaSki cells to paclitaxel.
@en
type
label
Inhibition of the mammalian ta ...... of CaSki cells to paclitaxel.
@ast
Inhibition of the mammalian ta ...... of CaSki cells to paclitaxel.
@en
prefLabel
Inhibition of the mammalian ta ...... of CaSki cells to paclitaxel.
@ast
Inhibition of the mammalian ta ...... of CaSki cells to paclitaxel.
@en
P2093
P1476
Inhibition of the mammalian ta ...... of CaSki cells to paclitaxel.
@en
P2093
Minegishi T
Nakazato T
P304
P356
10.1016/J.EJCA.2005.12.018
P577
2006-03-15T00:00:00Z